{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T01:16:40Z","timestamp":1776475000989,"version":"3.51.2"},"reference-count":25,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,5,22]],"date-time":"2012-05-22T00:00:00Z","timestamp":1337644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2013,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Irinotecan is highly active against rhabdomyosarcoma (RMS), yet its tolerability and efficacy in combination with radiation is unknown. We examined local control and toxicities in RMS patients treated with radiotherapy (RT) in combination with radiosensitizing agents irinotecan\u2009+\u2009carboplatin (I\u2009+\u2009C).<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedure<\/jats:title><jats:p>From 11\/2003 to 1\/2011, 60 patients were enrolled on a pilot phase II protocol with newly diagnosed intermediate\u2010 or high\u2010risk RMS at Memorial Sloan\u2010Kettering Cancer Center. Induction therapy consisted of two cycles of I\u2009+\u2009C followed by three cycles of vincristine, doxorubicin, and cyclophosphamide. At week 13, 47 patients received definitive primary\u2010site RT or post\u2010operative RT with two concurrent cycles of I\u2009+\u2009C. Median RT dose was 50.4\u2009Gy (range 30.6\u201350.4\u2009Gy). Radiation\u2010related toxicities were evaluated according to the Common Terminology Criteria for Adverse Events, version 3.0.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Median age of the cohort was 9 years. With median follow\u2010up of 32 months, 2.5 year actuarial local control was 89%. Among all patients, grades 3 and 4 dermatitis were observed in 11% and 4%, respectively. Among parameningeal, orbit, and other head\/neck sites, rates of grades 3 and 4 mucositis were 20% and 10%, respectively. Among abdomen\/pelvis sites, 12% developed grade 3 diarrhea and 6% developed grade 3 cystitis. No treatment breaks were necessary.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Preliminary results of irinotecan and carboplatin administered with concurrent RT in intermediate\u2010 and high\u2010risk RMS demonstrated favorable tolerability, efficacy, and local control. Reduced rates of acute grades 3\u20134 mucositis were observed when compared with historical results. Pediatr Blood Cancer 2013;60:242\u2013247. \u00a9 2012 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.24205","type":"journal-article","created":{"date-parts":[[2012,5,22]],"date-time":"2012-05-22T21:43:34Z","timestamp":1337723014000},"page":"242-247","source":"Crossref","is-referenced-by-count":24,"title":["Concurrent radiation with irinotecan and carboplatin in intermediate\u2010 and high\u2010risk rhabdomyosarcoma: A report on toxicity and efficacy from a prospective pilot phase II study"],"prefix":"10.1002","volume":"60","author":[{"given":"Kavita V.","family":"Dharmarajan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard H.","family":"Wexler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne L.","family":"Wolden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,5,22]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1080\/13577140120048890"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.1.213"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.05.184"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.15.3463"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199807000-00006"},{"key":"e_1_2_7_7_2","first-page":"2823","article-title":"Therapeutic efficacy of the topoisomerase I inhibitor 7\u2010ethyl\u201010\u2010(4\u2010[1\u2010piperidino]\u20101\u2010piperidino)\u2010carbonyloxy\u2010camptothecin against human tumor xenografts: Lack of cross\u2010resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9\u2010dimethylaminomethyl\u201010\u2010hydroxycamptothecin","volume":"53","author":"Houghton PJ","year":"1993","journal-title":"Cancer Res"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00686188"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.6.1815"},{"key":"e_1_2_7_10_2","first-page":"32","article-title":"A phase I study of irinotecan in pediatric patients: A pediatric oncology group study","volume":"7","author":"Blaney S","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_7_11_2","first-page":"563a","article-title":"A Phase trial of irinotecan (CPT\u201011) in children","volume":"18","author":"Vassal G","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200202000-00009"},{"key":"e_1_2_7_13_2","unstructured":"WexlerLH.Data presented at the Connective Tissue Oncology Society 2001 Annual Meeting. West Palm Beach FL 2001."},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690233"},{"key":"e_1_2_7_15_2","first-page":"43","article-title":"Weekly irinotecan and concurrent radiation therapy for stage III unresectable NSCLC","volume":"14","author":"Choy H","year":"2000","journal-title":"Oncology (Williston Park)"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25349"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603328"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.08.024"},{"key":"e_1_2_7_19_2","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/0959-8049(95)00665-6","article-title":"Response of previously untreated metastatic rhabdomyosarcoma to combination chemotherapy with carboplatin, epirubicin and vincristine","volume":"32","author":"Frascella E","year":"1996","journal-title":"Eur J Cancer"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23992"},{"key":"e_1_2_7_21_2","volume-title":"Common terminology criteria for adverse events (CTCAE)","author":"National Cancer Institute (U.S.)","year":"2003"},{"key":"e_1_2_7_22_2","unstructured":"National Cancer Institute.Phase III randomized study of vincristine dactinomycin and cyclophosphamide (VAC) versus VAC alternating with vincristine and irinotecan hydrochloride in combination with radiotherapy in patients with newly diagnosed intermediate\u2010risk rhabdomyosarcoma. clinical trials (PDQ) homepage.http:\/\/www.cancer.gov\/clinicaltrials\/search\/view?cdrid=487560&version=HealthProfessional. Published July 14 2006. Accessed March 29 2012."},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.01.036"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2005.07.299"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)01709-6"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2004.08.005"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.24205","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.24205","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.24205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T18:50:36Z","timestamp":1697655036000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.24205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,22]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["10.1002\/pbc.24205"],"URL":"https:\/\/doi.org\/10.1002\/pbc.24205","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,22]]}}}